26.03.2024 • NewsSandozantibioticinvestment

Sandoz Opens Antibiotic Production Facility in Austria

Sandoz, a generic and biosimilar medicines manufacturer, recently opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely in Europe.

The new facility and automated production lines will increase production capacity by 20% compared to the current capacity of 200 million packages per year. The expansion in finished dosage forms (FDF) means that Kundl now has a production capacity of 240 million packages per year, more than a doubling from 2021 output levels. The new facility is part of a €200 million investment into the site in Kundl, to significantly upgrade penicillin API manufacturing and increase output of finished products.

Gilbert Ghostine, Chairman Sandoz, commented "Antibiotics are the backbone of modern medicine and Kundl is a testament to the resilience of European manufacturing. We are proud to further strengthen our manufacturing capabilities in Austria. This allows us to address growing demand and further strengthens our commitment to our unique European-based antibiotic production network."

With a manufacturing area of 3,000m2, innovative technologies enable the production of one billion additional penicillin tablets and a doubling of the quantity of powder oral suspensions (POS), which are mainly used in pediatric medicines. 

 

Sandoz has the only major remaining vertically integrated production network for penicillin in Europe. From active pharmaceutical ingredients (API) to FDF, Sandoz produces penicillin, the leading category of antibiotics worldwide, in Austria.

Richard Saynor, CEO Sandoz, said, "Kundl, as the hub and center of our antibiotic production, is a true lighthouse project when it comes to security of antibiotic supply. This investment is our contribution to fighting shortages and increasing access for patients. To be successful in the future, we need to join forces across healthcare systems and build a sustainable market environment for generic medicines, focused on what is best for patients."

Company

Sandoz AG

Forum 1
CH-4056 Basel
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.